Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-09-24

FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved Lupin Pharmaceuticals' supplemental application for Levothyroxine Sodium (generic levothyroxine) under ANDA 209713.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVOTHYROXINE SODIUM (levothyroxine sodium)

Snippet

SUPPL AP for LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)